Rajeev Saggar Sells 1,649 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 1,649 shares of Liquidia stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $13.68, for a total value of $22,558.32. Following the transaction, the insider now owns 211,672 shares of the company’s stock, valued at approximately $2,895,672.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Liquidia Stock Down 1.4 %

Liquidia stock opened at $12.37 on Friday. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The company’s 50 day moving average price is $14.55 and its two-hundred day moving average price is $11.19. The stock has a market cap of $940.47 million, a P/E ratio of -10.31 and a beta of 0.16.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The firm had revenue of $4.53 million for the quarter, compared to the consensus estimate of $5.29 million. On average, equities analysts anticipate that Liquidia Co. will post -1.01 EPS for the current year.

Analyst Upgrades and Downgrades

LQDA has been the subject of a number of analyst reports. HC Wainwright lifted their price target on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Liquidia in a research note on Wednesday, April 10th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently modified their holdings of the company. Simplicity Wealth LLC bought a new position in shares of Liquidia during the 1st quarter worth approximately $490,000. Bluefin Capital Management LLC bought a new stake in shares of Liquidia in the 4th quarter worth approximately $302,000. Birchview Capital LP bought a new stake in shares of Liquidia in the 4th quarter worth approximately $241,000. Kynam Capital Management LP raised its holdings in shares of Liquidia by 34.9% in the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares during the period. Finally, Vestal Point Capital LP bought a new stake in shares of Liquidia in the 4th quarter worth approximately $12,331,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).